On October 30, 2015, Kantor & Kantor LLP filed a class action lawsuit against Blue Shield of California. Later we amended the complaint to include “California Physicians’ Service doing business as Blue Shield of California.” Both Defendants are being sued for their unlawful denial of coverage and refusal to pay for “Harvoni,” an amazing drug that can seemingly cure chronic Hepatitis C (also sometimes referred to as “CHC”). Harvoni, developed by Gilead Sciences, Inc., is now viewed by doctors as a medically necessary treatment for Hepatitis C.
About Hepatitis C and Harvoni
Hepatitis C is a widespread contagious disease that can lead to severe liver damage, cancer, and even death. In October 2014, the United States Food and Drug Administration approved Harvoni for the treatment of Hepatitis C. Harvoni is the first drug approved for the treatment of chronic Hepatitis C that does not require combination with other drugs, and can effectively cure chronic Hepatitis C in 94% to 100% of cases with little to no side effects.
Alleged Unlawful Conduct
Notwithstanding the life-saving treatment offered to CHC patients by Harvoni, Defendants have unlawfully limited Plaintiff’s and class members’ access to this drug by developing arbitrary coverage criteria.
As detailed in the complaint, Plaintiff and class members were diagnosed with Hepatitis C and prescribed Harvoni by their physicians. Defendants then unjustifiably and unlawfully denied coverage of Harvoni for its insureds. As a result, Plaintiff and class members have been and continue to be irreparably damaged by Defendants’ denial of coverage for the Harvoni treatment.
If you or someone you know was denied Harvoni treatment by Blue Shield of California, or by any insurance company or HMO, and would like our help, or just have questions, please contact us today at 877-783-8686 or by email at firstname.lastname@example.org.